Elias Aboujaoude, MD, MA
Publication Details
-
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
J Clin Psychopharmacol. 2009; (1): 51-5
Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD.
Help
Trial Administration